Journal
SCIENCE TRANSLATIONAL MEDICINE
Volume 10, Issue 459, Pages -Publisher
AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/scitranslmed.aat7807
Keywords
-
Categories
Funding
- Department of Radiation Oncology at Weill Cornell Medicine (New York)
- Luke Heller TECPR2 Foundation (Boston)
- Sotio a.s. (Prague, Czech Republic)
- Ludwig Institute for Cancer Research
- Parker Institute for Cancer Immunotherapy
- Swim Across America
- National Cancer Institute [P30CA008748]
- Ono Pharmaceuticals
- Ligue contre le Cancer (equipe labellisee)
- Agence National de la Recherche (ANR)-Projets blancs
- ANR
- ERA-Net for Research on Rare Diseases
- Association pour la recherche sur le cancer (ARC)
- Canceropole Ile-de-France
- Chancelerie des universites de Paris (Legs Poix)
- Fondation pour la Recherche Medicale (FRM)
- European Commission (ArtForce)
- ERA Network on Cardiovascular Diseases (ERA-CVD, MINOTAUR)
- European Research Council (ERC)
- Fondation Carrefour
- Institut National du Cancer (INCa)
- INSERM (HTE)
- Institut Universitaire de France
- LeDucq Foundation
- LabEx Immuno-Oncology
- RHU Torino Lumiere
- Seerave Foundation
- SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE)
- SIRIC Cancer Research and Personalized Medicine (CARPEM)
- Paris Alliance of Cancer Research Institutes (PACRI)
- Elior
- Phosplatin (New York)
- NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Immunotherapy is revolutionizing the clinical management of multiple tumors. However, only a fraction of patients with cancer responds to immunotherapy, and currently available immunotherapeutic agents are expensive and generally associated with considerable toxicity, calling for the identification of robust predictive biomarkers. The overall genomic configuration of malignant cells, potentially favoring the emergence of immunogenic tumor neoantigens, as well as specific mutations that compromise the ability of the immune system to recognize or eradicate the disease have been associated with differential sensitivity to immunotherapy in preclinical and clinical settings. Along similar lines, the type, density, localization, and functional orientation of the immune infiltrate have a prominent impact on anticancer immunity, as do features of the tumor microenvironment linked to the vasculature and stroma, and systemic factors including the composition of the gut microbiota. On the basis of these considerations, we outline the hallmarks of successful anticancer immunotherapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available